Anticoagulant & Antiplatelet Reversal · Periprocedural Bridging

Anticoagulation Reversal

← noahpac
↻ Reviewed quarterly
Life-threatening bleeding: Do not wait for labs to start reversal in a hemodynamically unstable patient. Give reversal agent, activate massive transfusion protocol if indicated, and pursue source control (endoscopy, surgery, IR) in parallel. Hematology consult for complex or refractory cases.
Reversal Agent — Quick Reference
Warfarin
Vitamin K antagonist
4F-PCC + Vitamin K 10 mg IV
Dosing depends on INR and bleeding severity — see table below
See severity table
Dabigatran (Pradaxa)
Direct thrombin inhibitor
Idarucizumab (Praxbind) 5 g IV
Two 2.5 g/50 mL vials, given ≤15 min apart. Onset within minutes. If unavailable: aPCC (FEIBA) or 4F-PCC; dabigatran is dialyzable (~60% removed in 2–3h) unlike other DOACs
Specific reversal agent
Apixaban / Rivaroxaban
Factor Xa inhibitors
4F-PCC 50 units/kg
Andexanet alfa (Andexxa) was withdrawn from the US market in 2026 and is no longer available — 4F-PCC per product labeling is now the primary reversal option in the US
No specific agent (US)
Edoxaban (Savaysa)
Factor Xa inhibitor
4F-PCC 50 units/kg
No FDA-approved specific reversal agent ever existed for edoxaban. 4F-PCC per manufacturer labeling, limited evidence
No specific agent
Aspirin
COX-1 inhibitor (irreversible)
Platelet transfusion (1 unit)
Reserve for life-threatening bleeding or neurosurgical emergency. Consider DDAVP (desmopressin) 0.3 mcg/kg IV to improve platelet function. No specific reversal agent
No specific agent
P2Y12 inhibitors
Clopidogrel, ticagrelor, prasugrel
Platelet transfusion
Ticagrelor's active drug and metabolite remain in plasma and can inhibit transfused platelets too — timing/effectiveness is less reliable than for clopidogrel/prasugrel. No specific reversal agent
No specific agent
Warfarin Reversal by Severity / INR
Life-threatening bleeding
Any INR. 4F-PCC (Kcentra) 25–50 units/kg based on INR and weight (per product labeling) plus Vitamin K 10 mg IV, given as a slow infusion (not push — risk of anaphylactoid reaction).
Major bleeding, not life-threatening
4F-PCC (preferred, faster correction) or FFP if PCC unavailable, plus Vitamin K 5–10 mg IV or PO.
INR > 10, no significant bleeding
Hold warfarin. Oral Vitamin K 2.5–5 mg. Recheck INR in 24h.
INR 4.5–10, no significant bleeding
Hold warfarin. Low-dose oral Vitamin K (1–2.5 mg) if high bleeding risk factors present; otherwise hold and recheck INR — routine Vitamin K not required for every patient in this range.
INR < 4.5, no significant bleeding
Hold or reduce dose. Vitamin K not routinely needed.
Periprocedural Bridging
Low–moderate thromboembolic risk
Most non-valvular AFib (CHA₂DS₂-VASc without prior stroke/TIA), provoked VTE >3 months prior. No bridging — hold anticoagulant per timing below, resume post-procedure once hemostasis is adequate. The BRIDGE trial showed bridging increases bleeding without reducing thromboembolic events in this group.
High thromboembolic risk
Mechanical mitral valve, any mechanical valve + prior stroke/TIA, VTE within 3 months, CHA₂DS₂-VASc with recent stroke. Bridge with therapeutic-dose LMWH or UFH while warfarin is held. DOACs generally still do not require bridging due to short half-life.
Warfarin hold timing
Stop 5 days prior to procedure. Check INR the day before (or day of) — give small dose of oral Vitamin K if still elevated. Resume within 24h post-procedure if hemostasis is adequate.
DOAC hold timing (apixaban/rivaroxaban)
Low bleed-risk procedure: hold 1–2 days. High bleed-risk procedure: hold 2–3 days. Extend by 1–2 days if CrCl <50 mL/min (longer for dabigatran, which is more renally dependent). Resume 24h (low-risk) to 48–72h (high-risk) post-procedure.
General Principles
Time since last dose
DOAC half-lives are short (~12h for most). Reversal may be unnecessary for minor bleeding if >2–3 half-lives have elapsed since the last dose. For major or life-threatening bleeding, reverse regardless of timing.
Renal function
All DOACs are partly renally cleared (dabigatran most, ~80%). Impaired renal function prolongs drug exposure and increases both bleeding risk and the likely need for reversal/dialysis consideration.
Dialyzability
Dabigatran is dialyzable (low protein binding). Apixaban, rivaroxaban, and edoxaban are highly protein-bound and not effectively removed by dialysis — reversal agent or PCC is the primary strategy.
When in doubt
Involve hematology early for refractory bleeding, combined anticoagulant/antiplatelet therapy, hepatic impairment, or when the reversal response is inadequate. Local hospital massive transfusion and reversal protocols take precedence over this general reference.